autologous cd34+ cells Report issue

Cell therapy Experimental
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

autologous cd34+ cells | autologous cd34+ cells genetically modified | autologous cd34+hpc stem cells | autologous cd34 positive cells | autologous cd34-positive stem cells | autologous cd34+ stem cells | autologous expanded cd34+ haemopoietic cells | autologous pb-cd34+ stem cells | blood forming stem cell (cd34+cd90+) | cd34+ autologous stem cell | cd34+ bone marrow stem cells | cd34+ cells | cd34 enriched stem cell | cd34+ peripheral blood stem cell | cd34-positive cells | cd34-selected peripheral blood stem cell | cd34 selected progenitor cells | dli | gene-modified cd34+ hematopoietic stem cells | gene-transduced autologous cd34+ stem cells | transduced cd34+ hematopoietic stem cell

Organizations (60)

Research & Development (60)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (54)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (54)


 

Adrenoleukodystrophy (Phase 1/Phase 2)

Anemia, Sickle Cell (Phase 2)

Angina Pectoris (Phase 3)

beta-Thalassemia (Phase 1/Phase 2)

Bone Marrow Failure Disorders (Phase 2)

Breast Neoplasms (Phase 1)

Cardiomyopathy, Dilated (Phase 2)

Cardiovascular Diseases (Phase 1)

Chest Pain (Phase 1)

Chimerism (Phase 2)

Chronic Limb-Threatening Ischemia (Phase 1/Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

COVID-19 (Phase 1)

Crohn Disease (Phase 1/Phase 2)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Diabetic Retinopathy (Phase 1)

Fanconi Anemia (Phase 1)

Heart Diseases (Phase 3)

Heart Failure (Phase 1)

Hematopoietic Stem Cell Transplantation (Phase 1)

Immune System Diseases (Phase 2)

Kidney Transplantation (Phase 2/Phase 3)

Leukemia (Phase 2)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 3)

Leukodystrophy, Metachromatic (Phase 2)

Liver Diseases (Phase 1/Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 2)

Lysosomal Storage Diseases (Phase 2)

Macular Degeneration (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Pancytopenia (Phase 1)

Peripheral Arterial Disease (Phase 1/Phase 2)

Peripheral Vascular Diseases (Phase 1/Phase 2)

Plasmacytoma (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Primary Immunodeficiency Diseases (Phase 2)

Retinal Diseases (Phase 1)

Retinal Vein Occlusion (Phase 1/Phase 2)

Retinitis Pigmentosa (Phase 1)

Severe Combined Immunodeficiency (Phase 1)

X-Linked Combined Immunodeficiency Diseases (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 47
  • # of Trial Organizations: 60

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue